Founders Capital Management LLC trimmed its stake in shares of Davita Inc (NYSE:DVA) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 92,971 shares of the company’s stock after selling 2,968 shares during the period. Davita makes up about 3.0% of Founders Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Founders Capital Management LLC owned approximately 0.05% of Davita worth $6,717,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds also recently made changes to their positions in DVA. Schroder Investment Management Group lifted its position in shares of Davita by 53.9% during the second quarter. Schroder Investment Management Group now owns 49,967 shares of the company’s stock worth $3,201,000 after purchasing an additional 17,497 shares in the last quarter. Accident Compensation Corp lifted its position in shares of Davita by 147.5% during the second quarter. Accident Compensation Corp now owns 15,100 shares of the company’s stock worth $978,000 after purchasing an additional 9,000 shares in the last quarter. Cibc World Markets Corp lifted its position in shares of Davita by 35.3% during the second quarter. Cibc World Markets Corp now owns 22,006 shares of the company’s stock worth $1,425,000 after purchasing an additional 5,746 shares in the last quarter. Flinton Capital Management LLC lifted its position in shares of Davita by 10.7% during the second quarter. Flinton Capital Management LLC now owns 152,830 shares of the company’s stock worth $9,898,000 after purchasing an additional 14,756 shares in the last quarter. Finally, Oak Associates Ltd. OH lifted its position in shares of Davita by 21.1% during the second quarter. Oak Associates Ltd. OH now owns 185,195 shares of the company’s stock worth $11,993,000 after purchasing an additional 32,285 shares in the last quarter. Institutional investors own 87.94% of the company’s stock.
In other Davita news, CEO Javier Rodriguez sold 22,532 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $67.48, for a total value of $1,520,459.36. Following the completion of the sale, the chief executive officer now owns 210,317 shares of the company’s stock, valued at $14,192,191.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James K. Hilger sold 5,608 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $69.46, for a total transaction of $389,531.68. Following the completion of the sale, the insider now directly owns 47,649 shares of the company’s stock, valued at approximately $3,309,699.54. The disclosure for this sale can be found here. Insiders sold 117,937 shares of company stock valued at $8,028,379 in the last ninety days. Insiders own 2.00% of the company’s stock.
Davita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.94 by ($0.13). Davita had a net margin of 3.40% and a return on equity of 13.31%. The business had revenue of $3.92 billion during the quarter, compared to analyst estimates of $3.91 billion. During the same quarter in the prior year, the company earned $0.95 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. equities analysts predict that Davita Inc will post 3.42 EPS for the current fiscal year.
Davita announced that its Board of Directors has approved a stock buyback plan on Tuesday, October 10th that permits the company to repurchase $1.50 billion in shares. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
A number of brokerages have recently issued reports on DVA. TheStreet upgraded shares of Davita from a “c” rating to a “b-” rating in a research report on Thursday, January 4th. Zacks Investment Research upgraded shares of Davita from a “strong sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Bank of America upgraded shares of Davita from a “neutral” rating to a “buy” rating and increased their price objective for the company from $75.00 to $85.00 in a report on Thursday, January 4th. SunTrust Banks set a $75.00 price objective on shares of Davita and gave the company a “hold” rating in a report on Thursday, December 21st. Finally, KeyCorp restated a “hold” rating on shares of Davita in a report on Tuesday, October 10th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the stock. Davita currently has a consensus rating of “Hold” and an average price target of $76.00.
TRADEMARK VIOLATION NOTICE: This article was posted by Week Herald and is the property of of Week Herald. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://weekherald.com/2018/01/10/founders-capital-management-llc-trims-stake-in-davita-inc-dva.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.